Andersons pediatric cardiology 1682
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.54 KB, 3 trang )
cardiomyopathy.JCardiovascMagnReson.
2015;17:34.
304.Toro-SalazarOH,GillanE,O'LoughlinMT,et
al.Occultcardiotoxicityinchildhoodcancer
survivorsexposedtoanthracyclinetherapy.Circ
CardiovascImaging.2013;6(6):873–880.
305.OlivieriLJ,KellmanP,McCarterRJ,etal.
Nativet1valuesidentifymyocardialchanges
andstratifydiseaseseverityinpatientswith
duchennemusculardystrophy.JCardiovasc
MagnReson.2016;18(1):72.
306.TandonA,VillaCR,HorKN,etal.Myocardial
fibrosisburdenpredictsleftventricularejection
fractionandisassociatedwithageandsteroid
treatmentdurationinduchennemuscular
dystrophy.JAmHeartAssoc.
2015;4(4):e001338.
307.GiardiniA,FentonM,AndrewsRE,DerrickG,
BurchM.Peakoxygenuptakecorrelateswith
survivalwithoutclinicaldeteriorationin
ambulatorychildrenwithdilated
cardiomyopathy.Circulation.
2011;124(16):1713–1718.
308.ChenCK,ManlhiotC,RussellJL,etal.The
utilityofcardiopulmonaryexercisetestingfor
thepredictionofoutcomesinambulatory
childrenwithdilatedcardiomyopathy.
Transplantation.2017.
309.KirkR,DipchandAI,RosenthalDN,etal.The
internationalsocietyforheartandlung
transplantationguidelinesforthemanagementof
pediatricheartfailure:executivesummary.
[corrected].JHeartLungTransplant.
2014;33(9):888–909.
310.MiyamotoSD,StaufferBL,NakanoS,etal.
Beta-adrenergicadaptationinpaediatric
idiopathicdilatedcardiomyopathy.EurHeartJ.
2014;35(1):33–41.
311.ZannadF,McMurrayJJ,KrumH,etal.
Eplerenoneinpatientswithsystolicheartfailure
andmildsymptoms.NEnglJMed.
2011;364(1):11–21.
312.PittB,ZannadF,RemmeWJ,etal.Theeffectof
spironolactoneonmorbidityandmortalityin
patientswithsevereheartfailure.Randomized
aldactoneevaluationstudyinvestigators.NEngl
JMed.1999;341(10):709–717.
313.RamanSV,HorKN,MazurW,etal.Eplerenone
forearlycardiomyopathyinduchennemuscular
dystrophy:arandomised,double-blind,placebocontrolledtrial.LancetNeurol.2015;14:153–
161.
314.CONSENSUSTrialStudyGroup.Effectsof
enalaprilonmortalityinseverecongestiveheart
failure.Resultsofthecooperativenorth
scandinavianenalaprilsurvivalstudy
(CONSENSUS).NEnglJMed.
1987;316(23):1429–1435.
315.InvestigatorsS,YusufS,PittB,etal.Effectof
enalaprilonsurvivalinpatientswithreducedleft
ventricularejectionfractionsandcongestive
heartfailure.NEnglJMed.1991;325(5):293–
302.
316.CohnJN,TognoniG,ValsartanHeartFailure
TrialInvestigators.Arandomizedtrialofthe
angiotensin-receptorblockervalsartaninchronic
heartfailure.NEnglJMed.2001;345(23):1667–
1675.
317.PfefferMA,SwedbergK,GrangerCB,etal.
Effectsofcandesartanonmortalityand
morbidityinpatientswithchronicheartfailure:
theCHARM-overallprogramme.Lancet.
2003;362(9386):759–766.
318.HarmonWG,SleeperLA,CunibertiL,etal.
Treatingchildrenwithidiopathicdilated
cardiomyopathy(fromthepediatric
cardiomyopathyregistry).AmJCardiol.
2009;104(2):281–286.
319.PuggiaI,MerloM,BarbatiG,etal.Natural
historyofdilatedcardiomyopathyinchildren.J
AmHeartAssoc.2016;5(7).
